Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults

Overview of attention for article published in Frontiers in oncology, May 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 16 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 6,535 followers.

New research: Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults: Objective Children and adolescents with recurrent and metastatic solid tumors… https://t.co

26 May 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.